Author

Nathan D VanderKraats

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:DNA methylation· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

John R Edwards· 2 shared Cesar Sanchez· 1 shared Christopher E Schlosberg· 1 shared James I McDonald· 1 shared Jeff F Hiken· 1 shared Jeremy Hoog· 1 shared Keith F Decker· 1 shared Kyle L Jung· 1 shared

Activity by Year

2016-2016 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioinformatics

John R Edwards

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MIGS: Methylation Interpolated Gene Signatures Determine Associations Between Differential Methylation and Gene Expression

Christopher E Schlosberg, Nathan D VanderKraats, John R Edwards

The paper introduces MIGS, a model that uses methylation data to predict gene expression changes, showing it outperforms existing methods and identifies methylation regions most predictive of expression changes.

bioRxiv · Jul 15, 2016Bioinformatics

Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer

Jeff F Hiken, James I McDonald, Keith F Decker, Cesar Sanchez, Jeremy Hoog, Nathan D VanderKraats, Kyle L Jung, Margaret Akinhanmi, Matthew J Ellis, John R Edwards

The paper identifies epigenetic activation of PTGER4 as a mechanism promoting resistance to aromatase inhibitors in breast cancer and suggests it as a potential therapeutic target.

bioRxiv · Jun 2, 2016Cancer Biology